Performing a risk-benefit analysis for older people presents a major challenge to the individual clinician who has to wrestle with an ever expanding evidence base that contains a relative paucity of good data on which to make important decisions because of the under-representation of older people in most studies looking at AF and its treatment. The emerging impact of a further risk factor for bleeding, namely that of microhaemorrhages, further complicates stroke prevention decision making. Up to 6% of healthy elders exhibit microhaemorrhages on magnetic resonance imaging, which have clearly been identified as a marker of increased haemorrhagic risk in patients treated with thrombolysis [4, 5] . Many risk factors such as hypertension and diabetes that are used to stratify stroke risk and inform decisions about anticoagulation have also been closely linked to small-vessel disease, linked with higher rates of intracerebral bleeding in prevention
